190 related articles for article (PubMed ID: 17568401)
21. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Martin PD; Warwick MJ; Dane AL; Cantarini MV
Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
[TBL] [Abstract][Full Text] [Related]
22. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil.
Bergman E; Lundahl A; Fridblom P; Hedeland M; Bondesson U; Knutson L; Lennernäs H
Drug Metab Dispos; 2009 Dec; 37(12):2349-58. PubMed ID: 19773540
[TBL] [Abstract][Full Text] [Related]
23. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
24. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
26. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Romaine SP; Bailey KM; Hall AS; Balmforth AJ
Pharmacogenomics J; 2010 Feb; 10(1):1-11. PubMed ID: 19884908
[TBL] [Abstract][Full Text] [Related]
27. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
28. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin.
He YJ; Zhang W; Tu JH; Kirchheiner J; Chen Y; Guo D; Li Q; Li ZY; Chen H; Hu DL; Wang D; Zhou HH
Drug Metab Dispos; 2008 Aug; 36(8):1453-6. PubMed ID: 18443034
[TBL] [Abstract][Full Text] [Related]
29. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Lee YJ; Lee MG; Lim LA; Jang SB; Chung JY
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):36-45. PubMed ID: 20040338
[TBL] [Abstract][Full Text] [Related]
30. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
31. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
Chung JY; Cho JY; Yu KS; Kim JR; Oh DS; Jung HR; Lim KS; Moon KH; Shin SG; Jang IJ
Clin Pharmacol Ther; 2005 Oct; 78(4):342-50. PubMed ID: 16198653
[TBL] [Abstract][Full Text] [Related]
32. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
33. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Zalikowski J; Chen Y; Kim K; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):329-40. PubMed ID: 25630984
[TBL] [Abstract][Full Text] [Related]
34. Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers.
Li Y; Jiang X; Lan K; Jiang Q
Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):221-7. PubMed ID: 20166442
[TBL] [Abstract][Full Text] [Related]
35. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Li R; Barton HA
Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
[TBL] [Abstract][Full Text] [Related]
36. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure.
Iusuf D; van Esch A; Hobbs M; Taylor M; Kenworthy KE; van de Steeg E; Wagenaar E; Schinkel AH
Mol Pharmacol; 2013 May; 83(5):919-29. PubMed ID: 23429889
[TBL] [Abstract][Full Text] [Related]
37. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine.
Jamei M; Bajot F; Neuhoff S; Barter Z; Yang J; Rostami-Hodjegan A; Rowland-Yeo K
Clin Pharmacokinet; 2014 Jan; 53(1):73-87. PubMed ID: 23881596
[TBL] [Abstract][Full Text] [Related]
38. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
Kitamura S; Maeda K; Wang Y; Sugiyama Y
Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
[TBL] [Abstract][Full Text] [Related]
39. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
40. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]